The funding round was led by Distributed Ventures and included participation from Idealab NY and Elements Health Ventures. Tuned plans to use the funding to contract with more employers and third party administrators, said Danny Aronson, co-founder and CEO of the startup.
New York healthcare startups received $3.9 billion of funding in 2022, compared to $9 billion in 2021, according to a new DHNY report. Biotech startups represented 22% of total funding in 2022, a stark difference from women’s health only representing 2%.
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
The $58 million funding round was led by Portage and included participation from PruVen Capital, Wing Venture Capital and others. With the funding, Angle Health plans to expand into additional markets and grow its membership.
Override provides chronic pain patients with a care team that includes a pain physician, a physical therapist, a psychologist and a coach. The company has received $3.5 million in seed funding and has acquired Take Courage Coaching.
The funding was led by Bold Capital Group. Other investors of the company include Khosla Ventures, WestRiver Group and Glico. In total, Viome has raised more than $150 million.
This funding round was led by Bain Capital Life Sciences and SV Health Investors. They join existing investors, including Bill Gates and Access Biotechnology. The money will be used to support several clinical trials.
In an era of escalating healthcare costs and a growing preference for natural, holistic approaches to health, The Impact Brands emerges as a collective of diverse brands dedicated to supporting overall wellness through natural means.
Biotech startup Senda Biosciences is developing technology that yields a new type of medicine with two programming components: one directs the therapy to go to a particular destination in the body while the second tells the therapy what to do once it gets there. With the Series C financing, Senda aims to reach the clinic in 2024.
Government-funded initiatives such as the Cancer Moonshot support not only the primary science that often serves as a foundation for medical advances, but also ensure that patients with rare cancers are not overlooked.
Ceryx's device, Cysoni, is designed to pace the heart in rhythm with a person's respiration, so that the heart rate and breathing are synced. This is typically the case for a healthy person, but for someone with heart failure, that link becomes severed, CEO Stuart Plant said.
The DNA currently used in genetic medicines research is synthesized by chemical methods. Ansa Biotechnologies employs faster and less expensive enzymes-based technology, and the startup has raised capital to scale up operations as it prepares to launch its service.
The TSX Venture Exchange has a strong history of helping early-stage health and life sciences companies raise patient capital for research and development.
Anti-infective drug discovery startup ArrePath has launched with $20 million in seed funding to advance the development of molecules that use a dual mechanism to kill bacteria. The Princeton University spinout says its approach could overcome the drug resistance bacteria are developing to currently available products.
The funding round was led by Wellington Management. The company sees its approach as a break from the industry's "disproportionate" focus on dialysis, which is used to treat people with kidney failure.
The company currently operates two centers, one in Cincinnati and the other in Crescent Springs, Kentucky. The Series A funding round led by JAZZ Venture Partners will allow the company to open new locations as well as offering virtual care.
Transformation Capital led the funding round with participation from Andreessen Horowitz, Frist Cressey Ventures, Edward Elmhurst Health, AlleyCorp. The new financing enables Memora to meet commercial demand , drive new partnerships and further improve the care delivery experience, said CEO Manav Sevak.
Ada Health closed its Series B round after a $30 million extension round. International investors Farallon Capital, Red River West and Bertelsmann Investments provided the additional funds. This follows an initial Series B raise of $90 million last May, which was led by Bayer's investment arm.